Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of
Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of directors.
Diatide is developing peptide-based imaging and therapy agentsthat are labeled with technetium-99m (SCAN 8/30/95). The firmplans to file a new drug application in 1997 for its lead product,an agent for the detection of deep vein thrombosis.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.